Zhaoke Ophthalmology (6622.HK): Raising the 2023-24E adjusted net loss forecast; lowering the target price
Mega Ophthalmology (6622.HK): Cyclosporin A with controllable cash expenditure for the full year of 2021 will soon be put into production
Mega Ophthalmology-B (6622.HK) 1H21 performance: Cyclosporin A eye gel phase III reaches the main end point All clinical trials are progressing according to plan
Expected to see Zhaoke Ophthalmology (6622.HK): Overfall and rebound
Zhaoke Ophthalmology Clinic (6622.HK): New ophthalmologist sets sail
Zhaoke Ophthalmology-B (06622.HK): Ophthalmology products are widely distributed and market growth can be expected
IPO: Zhaoke Ophthalmology (06622.HK)
IPO News: Zhaoke Ophthalmology Co., Ltd. - B (6622.HK)
IPO Report: Zhaoke Ophthalmology-B (6622.HK)
No Data
No Data